Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
ZOL Is Associated With Better DFS and RFS<br />
in a Multivariate Analysis<br />
Therapy<br />
No ZOL vs ZOL<br />
Tumor stage<br />
(T1 vs T2)<br />
Tumor grade<br />
(1/2 vs 3)<br />
Lymph node status<br />
(Negative vs positive)<br />
Progesterone receptor<br />
(neg, +, 2+ vs 3+)*<br />
Disease-free survival<br />
Recurrence-free survival<br />
0 0.25 0.5 0.75 1.0 1.25 1.5 1.75 2.0 2.25 2.5 2.75 3.0<br />
Hazard ratio<br />
Decreased risk Increased risk<br />
Median follow-up = 48 months<br />
DFS = Disease-free survival; RFS = Recurrence-free survival; ZOL = Zoledronic acid.<br />
*Reiner score for staining: + = 10 to 30%; ++ = 31 to 70%; +++ = 71 to 100%<br />
P value<br />
.022<br />
.028<br />
.023<br />
.036<br />
< .001<br />
< .001<br />
< .001<br />
< .001<br />
.001<br />
.001<br />
15
Change language